FDA and WHO identified semaglutide suicidal thought reports, exceeding those of other diabetes medications in the ...

A ustralia's drugs regulator has issued a fresh warning for users of high-profile injectable diabetes and weight-loss drugs such as Ozempic.

No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide. (HealthDay News) — For patients with ...

HOUSTON — The dual GLP-1/GIP receptor agonist tirzepatide showed significantly greater efficacy than the GLP-1 dulaglutide in the treatment of major kidney outcomes in patients with type 2 diabetes ...

ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced the latest in a series of the most significant actions ever taken by our Federal government to lower ...

Medicare will begin covering weight loss drugs in 2026 for the first time under a pricing agreement announced by the White House, according to a Nov. 6 press release. The agreements with Eli Lilly and ...

Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...

According to Novo Nordisk, this study was the first to compare these GLP-1 receptor agonists in a real-world setting. Findings from a real-world study evaluating cardiovascular disease-related ...

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity in a real-world survey of certain US patients. Medicare patients who took ...

Novo Nordisk's Ozempic reduces the risk of heart attack, stroke and death by 23% in people with type 2 diabetes and cardiovascular disease compared to rival drug dulaglutide, the company said Thursday ...

Mounjaro reduces major heart problems by 8% versus Trulicity in trial Death from any cause was 16% lower for patients on Mounjaro versus Trulicity Safety profile similar for both drugs July 31 ...

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity.